Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide, Bortezomib, and Melphalan in Advanced Multiple Myeloma
NCT01242267Phase 2Completed
- Sponsor
- Hackensack Meridian Health
- Start
- May 2010
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by Hackensack Meridian Health. Started May 2010; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT01242267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242267.